SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO's second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company's multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets an

SARASOTA, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. ("INVO") (NASDAQ:IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-8 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on November 28, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on November 28, 2025, the Company's common stock will trade on a post-split basis under the same trading symbol, "IVF". As a result of the reverse stock split, the CUSIP number for the Company's common stock will be 44984F807. As a result of the reverse stock split, every 8 shares of issued and outst

SARASOTA, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced third quarter 2025 financial results. Q3 2025 Financial Highlights (all metrics compared to Q3 2024 unless otherwise noted) Revenue was $1,757,094, an increase of 23% compared to $1,433,151.Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin, increased 21% to $1,722,223, compared to $1,418,011.Revenue from all clinics, including both con

MIDDLETON, Wis. and SARASOTA, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced a strategic partnership with Heidi Health to integrate its innovative AI-powered scribe platform at INVO's Wisconsin Fertility Institute (WFI). Built by doctors, Heidi Health adds a modern, AI-powered tool that works with providers' existing EHR systems, resulting in no rigid rebuilds or lost functionality. Heidi automates clinical documenta

SARASOTA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 5:00 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conferen

SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results. Q2 2025 Financial Highlights (all metrics compared to Q2 2024 unless otherwise noted) Revenue was $1,863,654, an increase of 1% compared to $1,836,597, a new quarterly record for the Company.Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin,

SARASOTA, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. ("INVO") (NASDAQ:IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-3 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on July 21, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on July 21, 2025, the Company's common stock will trade on a post-split basis under the same trading symbol, "IVF". As a result of the reverse stock split, the CUSIP number for the Company's common stock will be 44984F708. As a result of the reverse stock split, every 3 shares of issued and outstanding c

SARASOTA, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare company focused on the fertility market, today announced further efforts to drive its comprehensive strategy to enhance fertility services through expanded clinical and embryology training support and improved pricing for its innovative INVOcell® technology. This underscores the Company's dual mission as an innovator of cutting-edge fertility solutions and a provider of compassionate, patient-centered clinical care through its established fertility clinics and is complementary to the Company's focus on expanding its fertility clinic operations. INVOcell is

MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare company focused on the fertility market, is excited to announce the addition of Platelet-Rich Plasma (PRP) therapy to its comprehensive suite of fertility services at its Wisconsin Fertility Institute center. This cutting-edge treatment offers additional options for individuals and couples facing fertility challenges, further expanding the center's commitment to innovative, patient-centered care. PRP is a cutting-edge treatment that uses your body's own growth factors to stimulate uterine lining growth and ovarian rejuvenation, potenti

SARASOTA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare company focused on the fertility sector, today announced it has received a notice of allowance on a new patent for a modified version of the Company's proprietary INVOcell device. The new patent extends intellectual property protection on the Company's INVOcell device through 2040 based on a modified design which reflects feedback from leading embryologists to simplify use of the device. The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/949,960, titled "Intravaginal Culture Incubation C

4 - INVO Fertility, Inc. (0001417926) (Issuer)

4 - INVO Fertility, Inc. (0001417926) (Issuer)

4 - INVO Fertility, Inc. (0001417926) (Issuer)

4 - INVO Fertility, Inc. (0001417926) (Issuer)

4 - INVO Fertility, Inc. (0001417926) (Issuer)

4 - INVO Fertility, Inc. (0001417926) (Issuer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

10-Q - INVO Fertility, Inc. (0001417926) (Filer)

NT 10-Q - INVO Fertility, Inc. (0001417926) (Filer)

424B3 - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

S-1 - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO's second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company's multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets an

SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today announced fourth quarter and full year 2024 financial results. Q4 2024 Financial Highlights (all metrics compared to Q4 2023 unless otherwise noted) Revenue was $1,685,966, an increase of 22% compared to $1,381,754.Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin increased 24% to $1,687,300, compared to $1,362,938.Revenue from